Stay updated on Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.

Latest updates to the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page
- Check7 days agoChange DetectedNew entries 'Results Submission Events (1)' and 'Revision: v3.3.3' were added to the history, and 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe record history now shows a 'Results Submitted' entry, replacing the previous 'No Results Posted' status.SummaryDifference0.1%

- Check29 days agoChange DetectedThe page revision indicator changed from v3.3.1 to v3.3.2 on the Record History page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check36 days agoChange DetectedThe history lists a new revision entry (v3.3.1) and the removal of an earlier entry (v3.2.0). This seems to be a minor administrative update to the history display rather than a change to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoved the government funding and operating status notice from the page header/banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check57 days agoChange DetectedThe screenshots show the same Record History page with minor UI/layout changes and no updates to study data, status, or history entries. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vodobatinib for Ph+ CML: Safety & Efficacy Clinical Trial page.